Identification

Name
Dyclonine
Accession Number
DB00645  (APRD00940)
Type
Small Molecule
Groups
Approved
Description

Dyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It is also found in some varieties of the Cepacol sore throat spray.

Structure
Thumb
Synonyms
  • 1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone
  • 2-(1-Piperidyl)ethyl P-butoxyphenyl ketone
  • 3-Piperidino-4'-butoxypropiophenone
  • 4-Butoxy-beta-piperidinopropiophenone
  • 4-N-Butoxy-beta-(1-piperidyl)propiophenone
  • 4'-Butoxy-3-piperidinopropiophenone
  • Diclonina
  • Dyclocaine
  • Dyclonin
  • Dyclonine
  • Dycloninum
Product Ingredients
IngredientUNIICASInChI Key
Dyclonine hydrochlorideZEC193879Q536-43-6KNZADIMHVBBPOA-UHFFFAOYSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cepacol Sore Throat SpraySpray0.1 %OralReckitt Benckiser1999-07-012012-03-23Canada
PerioRinseRinse.1 g/100mLDental; Oral; Topical; TransmucosalCentura Pharmaceuticals, Inc2016-06-16Not applicableUs
Sore Throat ReliefLozenge3 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.Not applicableNot applicableCanada
Sucrets Black CherryLozenge3 mg/1OralInsight Pharmaceuticals2009-06-18Not applicableUs
Sucrets Childrens CherryLozenge1.2 mg/1OralInsight Pharmaceuticals2009-07-28Not applicableUs
Sucrets Extra Strength Mint Flav.loz 3mgLozenge3 mgOralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1994-12-311998-08-25Canada
Sucrets for KidsLozenge1.2 mgOralInsight Pharmaceuticals1997-08-15Not applicableCanada
Sucrets for KidsLozenge1.2 mgOralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1992-12-311998-08-25Canada
Sucrets MS WintergreenLozenge3 mg/1OralInsight Pharmaceuticals2009-07-28Not applicableUs
Sucrets Regular Strength Lemon Flav.loz 2mgLozenge2 mgOralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1994-12-311998-08-25Canada
International/Other Brands
Dyclone (AstraZeneca) / Sucrets (Insight Pharmaceuticals)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Ambix First AidDyclonine hydrochloride (.005 g/g) + Phenol (.005 g/g)CreamTopicalOrganics Corporation Of America Dba Ambix Laboratories2013-08-22Not applicableUs
Benzethonium chloride and Dyclonine hydrochlorideDyclonine hydrochloride (.23 mg/29.6mL) + Benzethonium chloride (.06 mg/29.6mL)LiquidTopicalWalgreen2012-01-12Not applicableUs
Benzethonium chloride Plus Dyclonine hydrochlorideDyclonine hydrochloride (.75 mg/10mL) + Benzethonium chloride (.2 mg/10mL)LiquidTopicalCVS Health2014-07-10Not applicableUs
Benzethonium chloride Plus Dyclonine hydrochlorideDyclonine hydrochloride (.75 mg/10mL) + Benzethonium chloride (.2 mg/10mL)LiquidTopicalHarmon Store Inc.2012-02-14Not applicableUs
Benzethonium chloride Plus Dyclonine hydrochlorideDyclonine hydrochloride (.75 mg/9mL) + Benzethonium chloride (.2 mg/9mL)LiquidTopicalChain Drug Consortium2005-12-07Not applicableUs
Benzethonium chloride Plus Dyclonine hydrochlorideDyclonine hydrochloride (.75 mg/10mL) + Benzethonium chloride (.2 mg/10mL)LiquidTopicalMeijer Distribution2012-01-05Not applicableUs
Cepacol Sore ThroatDyclonine hydrochloride (.1 g/100mL) + Glycerin (33 g/100mL)LiquidOralReckitt Benckiser2011-05-20Not applicableUs
Skin ShieldDyclonine hydrochloride (.0997 mL/27mL) + Benzethonium chloride (.0532 mL/27mL)LiquidTopicalInsight Pharmaceuticals2010-06-01Not applicableUs
Skin Shield Liquid BandageDyclonine hydrochloride (7.5 mg) + Benzethonium chloride (2 mg) + Ethanol (100 mg)LiquidTopicalDel Pharmaceuticals Inc.1983-12-311998-02-16Canada
Sucrets CompleteDyclonine hydrochloride (3 mg) + Menthol (6 mg)LozengeOralInsight Pharmaceuticals2007-05-31Not applicableCanada
Categories
UNII
078A24Q30O
CAS number
586-60-7
Weight
Average: 289.4125
Monoisotopic: 289.204179113
Chemical Formula
C18H27NO2
InChI Key
BZEWSEKUUPWQDQ-UHFFFAOYSA-N
InChI
InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3
IUPAC Name
1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one
SMILES
CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1

Pharmacology

Indication

Used to provide topical anesthesia of accessible mucous membranes prior to examination, endoscopy or instrumentation, or other procedures involving the esophagus, larynx, mouth, pharynx or throat, respiratory tract or trachea, urinary tract, or vagina. Also used to suppress the gag reflex and/or other laryngeal and esophageal reflexes to facilitate dental examination or procedures (including oral surgery), endoscopy, or intubation. Also used for relief of canker sores, cold sores or fever blister.

Structured Indications
Pharmacodynamics

Dyclonine is an oral anasthetic. If substantial quantities of local anesthetics are absorbed through the mucosa, actions on the central nervous system (CNS) may cause CNS stimulation and/or CNS depression. Actions on the cardiovascular system may cause depression of cardiac conduction and excitability and, with some of these agents, peripheral vasodilation.

Mechanism of action

Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.

TargetActionsOrganism
ASodium channel protein type 10 subunit alpha
inhibitor
Human
Absorption

Readily absorbed through mucous membranes into the systemic circulation. The rate of absorption is influenced by the vascularity or rate of blood flow at the site of application, the total dosage (concentration and volume) administered, and the duration of exposure. Absorption from mucous membranes of the throat or respiratory tract may be especially rapid.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

Approximately 30 to 60 minutes.

Clearance
Not Available
Toxicity

Symptoms of overdose include cardiovascular system depression, CNS toxicity, and methemoglobinemia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Dyclonine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dyclonine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dyclonine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dyclonine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dyclonine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dyclonine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Azaperone.Investigational, Vet Approved
AzelastineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Dyclonine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dyclonine is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dyclonine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dyclonine.Approved, Investigational
BuprenorphineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dyclonine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dyclonine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dyclonine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Dyclonine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dyclonine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dyclonine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dyclonine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dyclonine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Dyclonine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dyclonine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dyclonine.Approved
CocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dyclonine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dyclonine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dyclonine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dyclonine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dyclonine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dyclonine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Dyclonine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dyclonine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dyclonine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dyclonine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dyclonine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Dyclonine is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dyclonine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Dyclonine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dyclonine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dyclonine.Approved
EthanolDyclonine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dyclonine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dyclonine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dyclonine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dyclonine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dyclonine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dyclonine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dyclonine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dyclonine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dyclonine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dyclonine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Hexobarbital.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dyclonine.Approved, Investigational
HydrocodoneDyclonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dyclonine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Dyclonine is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dyclonine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dyclonine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dyclonine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dyclonine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dyclonine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dyclonine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dyclonine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Dyclonine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dyclonine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dyclonine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dyclonine.Approved
MethotrimeprazineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methylphenobarbital.Approved
MetyrosineDyclonine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dyclonine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Dyclonine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved, Investigational
MirtazapineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dyclonine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dyclonine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dyclonine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dyclonine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dyclonine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Dyclonine is combined with Opium.Approved, Illicit
OrphenadrineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dyclonine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dyclonine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dyclonine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dyclonine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dyclonine.Approved
ParaldehydeDyclonine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dyclonine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dyclonine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
PerazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dyclonine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dyclonine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dyclonine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dyclonine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pomalidomide.Approved
PramipexoleDyclonine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dyclonine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dyclonine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dyclonine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Dyclonine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dyclonine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Dyclonine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dyclonine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dyclonine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dyclonine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dyclonine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dyclonine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dyclonine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Romifidine.Vet Approved
RopiniroleDyclonine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dyclonine.Approved
RotigotineDyclonine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dyclonine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dyclonine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dyclonine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dyclonine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dyclonine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sultopride.Experimental
SuvorexantDyclonine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptDyclonine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dyclonine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrodotoxin.Investigational
ThalidomideDyclonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dyclonine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dyclonine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dyclonine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dyclonine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dyclonine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dyclonine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dyclonine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dyclonine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Dyclonine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Dyclonine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Dyclonine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dyclonine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dyclonine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zolazepam.Vet Approved
ZolpidemDyclonine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dyclonine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dyclonine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Tianjiang Sun, Xiaohong Gu, Hongguo Lu, Min Chen, "Oral Preparation of Dyclonine Hydrochloride." U.S. Patent US20080200506, issued August 21, 2008.

US20080200506
General References
Not Available
External Links
Human Metabolome Database
HMDB14783
KEGG Compound
C07881
PubChem Compound
3180
PubChem Substance
46506697
ChemSpider
3068
ChEBI
4724
ChEMBL
CHEMBL1201217
Therapeutic Targets Database
DAP000509
PharmGKB
PA164748037
Drugs.com
Drugs.com Drug Page
Wikipedia
Dyclonine
ATC Codes
N01BX02 — DyclonineR02AD04 — Dyclonine
AHFS Codes
  • 52:16.00 — Local Anesthetics
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentGingival Inflammation1

Pharmacoeconomics

Manufacturers
  • Astrazeneca lp
Packagers
Dosage forms
FormRouteStrength
CreamTopical
LiquidTopical
LiquidOral
SprayOral0.1 %
RinseDental; Oral; Topical; Transmucosal.1 g/100mL
LozengeOral3 mg/1
LozengeOral1.2 mg/1
LozengeOral
LozengeOral1.2 mg
LozengeOral2 mg
LozengeOral3 mg
AerosolOral.1 %
LozengeOral2 mg/1
GelTopical
Prices
Unit descriptionCostUnit
Dyclonine hcl powder4.9USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)174-175Bockstahler, E.R.; U.S.Patent 2,771,391; November 20,1956; assigned to Allied Laboratories, Inc. Florestano, H.J., Jeffries, S.F., Osborne, C.E. and Bahler, M.E.; U.S. Patent 2,868,689; January 13, 1959; assigned to Allied Laboratories, Inc.
water solubilitySoluble (HCl salt)Not Available
logP3.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.046 mg/mLALOGPS
logP4.11ALOGPS
logP3.68ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)15.88ChemAxon
pKa (Strongest Basic)8.36ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity87.07 m3·mol-1ChemAxon
Polarizability35.14 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9856
Caco-2 permeable+0.7155
P-glycoprotein substrateSubstrate0.7596
P-glycoprotein inhibitor IInhibitor0.8077
P-glycoprotein inhibitor IINon-inhibitor0.6392
Renal organic cation transporterInhibitor0.7801
CYP450 2C9 substrateNon-substrate0.8107
CYP450 2D6 substrateNon-substrate0.5142
CYP450 3A4 substrateSubstrate0.5313
CYP450 1A2 substrateInhibitor0.8914
CYP450 2C9 inhibitorInhibitor0.793
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8574
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5388
Ames testNon AMES toxic0.7961
CarcinogenicityNon-carcinogens0.8823
BiodegradationNot ready biodegradable0.7106
Rat acute toxicity2.3661 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8071
hERG inhibition (predictor II)Inhibitor0.6351
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Aryl alkyl ketones / Alkyl aryl ethers / Piperidines / Beta-amino ketones / Trialkylamines / Azacyclic compounds / Organopnictogen compounds
show 2 more
Substituents
Alkyl-phenylketone / Phenoxy compound / Benzoyl / Phenol ether / Aryl alkyl ketone / Alkyl aryl ether / Monocyclic benzene moiety / Beta-aminoketone / Piperidine / Benzenoid
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
piperidines, aromatic ketone (CHEBI:4724)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
Gene Name
SCN10A
Uniprot ID
Q9Y5Y9
Uniprot Name
Sodium channel protein type 10 subunit alpha
Molecular Weight
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Roghani S, Duperon DF, Barcohana N: Evaluating the efficacy of commonly used topical anesthetics. Pediatr Dent. 1999 May-Jun;21(3):197-200. [PubMed:10355012]
  4. Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. [PubMed:9476974]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18